FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ Dulbecco's Modified Eagle Medium (DMEM), Low Glucose, 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid

FluxMPS™ DCP-DMEMLH-QB1X is a Microfluidics Suitable, ultra-filtered DMEM Low Glucose + HEPES formulation engineered for microphysiological systems (MPS), organ-on-a-chip (OoC), and microfluidic tissue models. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration. Formulated without L-glutamine or sodium bicarbonate, with 25 mM HEPES (pKa 7.3 at 37°C) providing CO₂-independent buffering for open-top chip architectures.

• Low-glucose (1.0 g/L) DMEM formulated with 25 mM HEPES buffering (pKa 7.3 at 37°C) for CO₂-independent culture in open-top microfluidic and organ-on-a-chip platforms
• Manufactured without L-glutamine or sodium bicarbonate — add glutamine fresh at time of use; HEPES alone maintains pH stability
• Quadruple-stage filtration train (0.1 µm → 0.04 µm → 0.1 µm → 0.04 µm) reaching a 0.04 µm final cut-off — Microfluidics Suitable grade
• Endotoxin release specification < 0.05 EU/mL (LAL, USP <85>), tested per manufacturing batch, not per unit
• Contains sodium pyruvate (110 mg/L) as a supplemental carbon/energy source alongside 1.0 g/L D-glucose
• Manufactured under an ISO 13485:2016 quality management system with full lot traceability; final QC at Diagnocine's Totowa, NJ facility
• Custom pH, salt, HEPES concentration, and nutrient adjustments available on request

Engineered where standard media fails

Conventional 0.22 µm–filtered media passes mycoplasma-sized particles, subvisible particulates, and micro-aggregates that clog microfluidic channels and interfere with sensor readouts. FluxMPS™ is manufactured through a four-stage filtration train reaching a 0.04 µm final cut-off. HEPES buffering removes CO₂ dependency for open-top chip architectures and atmospheric incubation.

Quadruple-stage filtration system

Four sequential filtration stages reach a final 0.04 µm polish under aseptic conditions, delivering ultra-low particulate purity for microfluidic channel geometries.

1. 1

   0.1 µm Prefiltration I

   Removes large aggregates and particulates; protects the first 0.04 µm final filter.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains sub-micron particulates and micro-aggregates that a 0.22 µm filter passes through, including the 0.2–0.3 µm mycoplasma size range.

3. 3

   0.1 µm Prefiltration II

   A second, dedicated prefilter protecting the second 0.04 µm final filter cartridge.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; aseptic fill in an ISO Class 5 (Class 100) environment.

Designed for next-generation cell models

FluxMPS™ DCP-DMEMLH-QB1X supports platforms from single-channel microfluidic chips to multi-organ body-on-a-chip systems. The integrated 25 mM HEPES buffer suits open-top microfluidic devices and atmospheric CO₂ environments.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) MPS Grade variant is available on request for automated bioreactor perfusion and robotic liquid handlers — a separate, six-stage ultra nano-filtered product line distinct from this Microfluidics Suitable formulation.

• Total Particulate Exclusion: 10 nm filtration removes nanoparticulate aggregates
• Valve & Sensor Protection: Reduces micro-fouling risk to solenoid valves and inline optical sensors
• Extended Perfusion Stability: Consistent nutrient delivery over weeks-long culture

Inquiry Required: Contact support@diagnocine.com for the 0.01 µm MPS Grade variant.

Analytical release specifications

Every lot released against the full specification matrix. CoA: support@diagnocine.com.

Full composition (mg/L)

32 ingredients verified per lot with CAS numbers for full raw-material traceability.

Manufacturing & compliance

Every FluxMPS™ product is manufactured and released under a multi-layer quality system spanning raw materials, in-process controls, and final-product testing.

How DCP-DMEMLH-QB1X compares

FluxMPS™ DCP-DMEMLH-QB1X vs. conventional 0.22 µm–filtered DMEM Low Glucose + HEPES formulations.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-DMEMLH-QB1X.

Supporting literature

Key peer-reviewed publications supporting Microfluidics Suitable, ultra-filtered media in organ-on-a-chip and microfluidic research.

1. Huh D, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328:1662–1668. doi:10.1126/science.1188302
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. doi:10.1038/nbt.2989
3. Ham RG. Clonal growth of mammalian cells in a chemically defined, synthetic medium. Proc Natl Acad Sci USA. 1965;53:288–293. doi:10.1073/pnas.53.2.288
4. Novak R, et al. Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nat Biomed Eng. 2020;4:407–420. doi:10.1038/s41551-019-0497-x
5. Jang KJ, et al. Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol. 2013;5:1119–1129. doi:10.1039/c3ib40049b
6. Schimek K, et al. Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip. 2013;13:3588–3598. doi:10.1039/c3lc50217a
7. Luni C, et al. High-efficiency cellular reprogramming with microfluidics. Nat Methods. 2016;13:446–452. doi:10.1038/nmeth.3832
8. Sung JH, et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip. 2013;13:1201–1212. doi:10.1039/c3lc41017j